4 Analysts Have This to Say About Gracell Biotechnologies
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Gracell Biotechnologies (NASDAQ:GRCL) stock. The company has an average price target of $16.0 with a high of $20.00 and a low of $11.00. This average price target has increased by 14.29% over the past month.
August 30, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given positive ratings to Gracell Biotechnologies (NASDAQ:GRCL) stock, with an average price target of $16.0, which has increased by 14.29% over the past month.
The positive ratings from analysts and the increase in the average price target over the past month indicate a bullish sentiment towards Gracell Biotechnologies. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100